DP
Areas of Expertise

Many doctors have expertise treating multiple conditions. MediFind uses a variety of data sources to determine what conditions a doctor treats and their level of experience.

Check Dr. Devang J. Pastakia's experience treating your condition:
About Dr. Devang J. Pastakia

Devang Pastakia is a Pediatric Hematologist Oncology specialist and a Pediatrics expert in Nashville, Tennessee. Pastakia has been practicing medicine for over 19 years and. His top areas of expertise are Gliomatosis Cerebri, Glioma, Pineocytoma, and Pineoblastoma. He is licensed to treat patients in Tennessee and Maryland. Pastakia is currently accepting new patients.

His clinical research consists of co-authoring 8 peer reviewed articles and participating in 8 clinical trials in the past 15 years.

Insurance

MediFind strives to display the most accurate insurance information for every doctor. If you do not see your insurance listed for Dr. Devang J. Pastakia it is best to call his office and ask if your insurance is accepted.


Dr. Devang J. Pastakia accepts the following insurance:

  •  Blue Cross Blue Shield
  •  Ambetter
  •  Cigna
  •  Alliant Health

Call to see if your plan is accepted.
Locations
2200 Childrens Way, Nashville, TN 37232
Background & Education
Graduate Institution
UMDNJ-New Jersey Medical School, 2003
Specialties
Pediatric Hematology Oncology
Pediatrics
Licenses
Pediatrics in MD
Hospital Affiliations
Vanderbilt University Medical Center
Languages Spoken
English
Gender
Male
Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Doctors who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.


8 Clinical Trials

NMTT- Neuroblastoma Maintenance Therapy Trial Using Difluoromethylornithine (DFMO)
A Phase 2 Study of Dabrafenib (NSC# 763760) With Trametinib (NSC# 763093) After Local Irradiation in Newly-Diagnosed BRAF V600-Mutant High-Grade Glioma (HGG)
A Phase 3 Randomized Study of Selumetinib Versus Carboplatin/Vincristine in Newly Diagnosed or Previously Untreated Neurofibromatosis Type 1 (NF1) Associated Low-Grade Glioma (LGG)
A Phase 2 Study of Reduced Therapy for Newly Diagnosed Average-Risk WNT-Driven Medulloblastoma Patients
Neuroblastoma Biology Studies
Utilizing Response- and Biology-Based Risk Factors to Guide Therapy in Patients With Non-High-Risk Neuroblastoma
Molecular-guided Therapy for the Treatment of Patients With Relapsed and Refractory Childhood Cancers
View 1 Less Clinical Trial -

Save this doctor for later
Sign Up
Looking for the best doctor for you?
Start Here
Is this your doctor?
Find a second opinion
Not sure about your diagnosis?
Check Your Symptoms
 
 
 
 
Learn about our expert tiers
Learn more
Similar Doctors